BiotechTube
BioWave

BioWave

Port Washington, United States· Est.
biowave.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $23M

Overview

BioWave is a commercial-stage medical device company focused on non-invasive, high-frequency peripheral nerve stimulation for pain relief. Its core technology differentiates from superficial TENS units by delivering stimulation deep to the nerve to block pain signal transmission, offering hours of relief post-treatment. With multiple FDA-cleared products (BioWavePRO, HOME, GO, PENS) and a significant contract with the US Veterans Administration, the company targets the large chronic and acute pain markets, emphasizing drug-free alternatives. BioWave operates as a private company, generating revenue through device sales to providers, patients, and institutional partners.

Pain Management

Technology Platform

Patented high-frequency peripheral nerve stimulation platform that delivers electrical signals through the skin to inhibit pain signal propagation in nerves, providing deep, long-lasting relief compared to superficial TENS.

Funding History

2
Total raised:$23M
Series A$20M
Seed$3M

Opportunities

The massive and growing market for non-opioid pain solutions, driven by the opioid crisis, presents a major opportunity.
BioWave's established VA contract provides a stable foundation and powerful reference customer for expansion into other institutional settings, sports medicine, and direct-to-consumer channels.

Risk Factors

Key risks include intense competition from larger neuromodulation companies, the challenge of securing widespread private insurance reimbursement, and the need for more robust randomized controlled trial data to fully convince the medical community of its superiority over existing therapies like TENS.

Competitive Landscape

BioWave competes in the neuromodulation for pain market, directly against traditional TENS device makers and indirectly against more invasive spinal cord stimulator companies. Its key differentiation is claiming deeper penetration and longer-lasting relief from short treatment sessions compared to surface-level TENS, positioning it between low-cost TENS and high-cost implantable systems.

More companies in Digital Health & Biotech SaaS →More companies in United States →